Contact Us marketing@medicilon.com
CN
×
Close Button
Medicilon Events
News and Events

Medicilon Events

Hot information:
Medicilon Appoints Dr. Liu Jian as President of Drug Discovery Division| Medicilon and Wuhan biolake successfully organized a biopharmaceutical salon| Medicilon FTE services & FFS services - flexible and efficient cooperation model
Nov 24,2020
Medicilon Wish You a Safe, Healthy and Warm Thanksgiving
#medicilon #thanksgiving #drugdiscovery
More
Medicilon Wish You a Safe, Healthy and Warm Thanksgiving
Nov 16,2020
Medicilon will participate ACT 2020 Annual Meeting
#Medicilon will exhibit the ACT 2020 Annual Meeting Nov 12-19.  Please visit our virtual booth for our #toxicology services.  We look forward to see you.
More
Medicilon will participate ACT 2020 Annual Meeting
Nov 11,2020
Medicilon will participate SAPA-CT Annual Conference
Medicilon will exhibit the SAPA-CT Annual Conference on Nov 14, 2020.  Our CEO, Dr. Chunlin Chen, is invited to give a presentation on the topic
More
Medicilon will participate SAPA-CT Annual Conference
Oct 31,2020
ABM Therapeutics presented Medicilon with a commemorative trophy of "our first candidate compound"
On October 31, 2020, ABM Therapeutics awarded the "Our First Candidate Compound" commemorative trophy to Dr. Li Zhigang, Vice President of Research and Development of Medicilon Chemistry Department, to thank Medicilon for its FTE form of cooperation, the pharmaceutical and chemical team helped it discover and advance the first drug candidate ABM-1310 to enter the clinical phase I in the United States.
More
ABM Therapeutics presented Medicilon with a commemorative trophy of "our first candidate compound"
Oct 19,2020
Medicilon-Phenomenex Chiral Segmentation Joint Laboratory Unveiling Ceremony
Shanghai, China, October 15, 2020-Shanghai Medicilon and Phenomenex reached a strategic agreement to jointly build a chemistry laboratory for chiral interchange and further enhance the
More
Medicilon-Phenomenex Chiral Segmentation Joint Laboratory Unveiling Ceremony
Oct 17,2020
Medicilon won two awards at The 15th Award of competitive and trustworthy listed companies
Oct 16th, Hainan, China—The 15th Award of competitive and trustworthy listed companies in China was held in Sanya, Hainan. The theme of the forum was
More
Medicilon won two awards at The 15th Award of competitive and trustworthy listed companies
Sep 28,2020
Medicilon will participate 2020 SAPA Annual Conference
Due to the COVID-19 pandemic, the 2020 SAPA Healthcare Investment Forum & Roadshow will be divided in 2 parts.  Part I will be hosted as
More
Medicilon will participate 2020 SAPA Annual Conference
Sep 21,2020
Medicilon is honored as TOP 20 R&D CRO Enterprises in China
Chongqing, September 10, 2020 – 2020 Conference on High Quality Development of Healthcare Industry & the Fifth China Pharmaceutical R&D and Innovation Summit was held
More
Medicilon is honored as TOP 20 R&D CRO Enterprises in China
Sep 05,2020
Online Seminar for Identification and validation of novel therapeutic targets in both breast and kidney cancers
Please reserve for your seat at the below eventbrite link for free. https://www.eventbrite.com/e/novel-therapeutic-targets-in-both-breast-and-kidney-cancers-tickets-119195604261 Hypoxia is associated with resistance towards radiation and chemotherapy. As tumors grow,
More
Online Seminar for Identification and validation of novel therapeutic targets in both breast and kidney cancers
Aug 20,2020
A seminar on preclinical R&D strategic cooperation was held between Medicilon and Yichang Humanwell
Yichang, Hubei, Aug 13, 2020 – A seminar on preclinical R&D strategic cooperation was held between Medicilon. INC (Stock Code: 688202. SH) and Yichang Humanwell
More
A seminar on preclinical R&D strategic cooperation was held between Medicilon and Yichang Humanwell
Aug 13,2020
Medicilon will participate in ACS Fall 2020 Virtual Meeting & Expo
Medicilon will exhibit the ACS Fall 2020 Virtual Meeting & Expo from Aug 17-20.  Please visit https://calendly.com/fywang to schedule a 1-on-1 meeting with our VP
More
Medicilon will participate in ACS Fall 2020 Virtual Meeting & Expo
Aug 13,2020
Application of Solid Dispersion Technology in Formulation Development
On July 20, 2020, DAC Biotech's new ADC drug development, TROP2-ADC—DAC-002 was approved of clinical study by NMPA. for the indication of solid malignant tumor.
More
Application of Solid Dispersion Technology in Formulation Development